This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.